WVE

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.